血管拡張薬の世界市場レポート 2025年

血管拡張薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.4％で87億5,000万米ドルに成長します。予測期間の成長は、高血圧と心血管疾患の有病率の上昇、心臓疾患に対する高度医療技術への需要の高まり、世界の高齢者の増加、糖尿病と高血圧の有病率の上昇、個別化医療の重要性の高まりに起因すると考えられます。予測期間における主要動向としては、戦略的合併・買収、外来診療や在宅医療へのシフト、製品イノベーション、技術進歩、医療インフラの拡大などが挙げられます。

血管拡張薬市場は、心血管疾患の罹患率の増加により成長が見込まれています。冠動脈疾患、心不全、脳卒中などを含むこれらの疾患は、高血圧やその他の危険因子と関連していることが多く、座りがちなライフスタイル、不健康な食生活、肥満、タバコの使用、高齢化などがその要因となっています。血管拡張薬は、血管を弛緩させ、血圧を下げ、血流を促進することによって、心血管疾患の管理に重要な役割を果たしています。例えば、2024年5月、米国の政府機関である疾病対策予防センター（CDC）は、2022年には心臓病が70万2,880人の死亡の原因となり、これは死亡者の5人に1人に相当すると報告しました。米国では毎年、約80万5,000人が心臓発作に苦しんでいます。このうち60万5,000人は初めての心臓発作であり、20万人は以前に心臓発作を経験したことがある人です。したがって、心血管疾患の増加傾向は、血管拡張薬市場拡大の重要な促進要因です。

座りがちなライフスタイルの増加が血管拡張薬市場の成長を促進すると予想されます。限られた身体活動と長時間の座位または横臥を特徴とする座りがちなライフスタイルは、技術やデスクワークなどの現代的な利便性により一般的になりつつあります。この動向に拍車をかけているのが、技術の進歩と、移動よりも利便性を優先する職場環境です。血管拡張薬は、血流を改善し、高血圧を軽減することで、座りっぱなしのライフスタイルに伴う心血管リスクを軽減する上で重要な役割を果たしています。例えば、2023年9月に米国疾病予防管理センターが発表したデータによると、成人の肥満率が35％以上の州は、2021年の19州から22州に増加し、座りがちなライフスタイルの影響が拡大していることが浮き彫りになりました。この動向は血管拡張薬市場の成長促進要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の血管拡張薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の血管拡張薬市場：成長率分析
• 世界の血管拡張薬市場の実績：規模と成長、2019～2024年
• 世界の血管拡張薬市場の予測：規模と成長、2024～2029年、2034年
• 世界の血管拡張薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の血管拡張薬市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 動脈拡張薬
• 静脈拡張薬
• 混合拡張薬
• 世界の血管拡張薬市場：薬剤別、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ニトログリセリン
• アルプロスタジル
• ミノキシジル
• ソルビトレート
• その他
• 世界の血管拡張薬市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• 高血圧
• 狭心症
• 心不全
• その他
• 世界の血管拡張薬市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 非経口
• その他
• 世界の血管拡張薬市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 在宅医療
• 専門センター
• その他
• 世界の血管拡張薬市場、動脈拡張薬のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• カルシウムチャネル遮断薬
• 一酸化窒素供与体
• カリウムチャネル活性化剤
• 世界の血管拡張薬市場、静脈拡張薬のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 硝酸塩
• 亜硝酸塩
• ホスホジエステラーゼ阻害剤（PDE5阻害剤）
• 世界の血管拡張薬市場、混合拡張薬のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• αアドレナリン拮抗薬
• アンジオテンシンII受容体拮抗薬（ARB）
• ACE阻害剤（アンジオテンシン変換酵素阻害剤）

第7章 地域別・国別分析

• 世界の血管拡張薬市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の血管拡張薬市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 血管拡張薬市場：競合情勢
• 血管拡張薬市場：企業プロファイル
  • Pfizer Inc.
  • Merck & Co. Inc.
  • AbbVie Inc.
  • Novartis AG
  • Sanofi S.A.

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• Abbott Laboratories
• GlaxoSmithKline Plc.
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• AstraZeneca
• Mayo Foundation for Medical Education and Research（MFMER）
• Boehringer Ingelheim International GmbH
• Bayer AG
• Viatris Inc.
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Biogen

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 血管拡張薬市場、2029年：新たな機会を提供する国
• 血管拡張薬市場、2029年：新たな機会を提供するセグメント
• 血管拡張薬市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Vasodilators are medicines that expand blood vessels by relaxing the smooth muscle cells in vessel walls, particularly in large arteries and veins. They are prescribed to manage conditions such as hypertension (high blood pressure), angina (chest pain), and heart failure, aiming to lessen the heart's workload and enhance circulation.

The primary types of vasodilators include arterial dilators, venous dilators, and mixed dilators. Arterial dilators primarily widen arteries, improving blood flow from the heart throughout the body. Examples of these medications are nitroglycerin, alprostadil, minoxidil, and sorbitrate. They are administered via oral, parenteral, and other routes, and are utilized across various settings including hospitals, homecare, specialty centers, among others.

The vasodilators market research report is one of a series of new reports from The Business Research Company that provides vasodilators market statistics, including vasodilators industry global market size, regional shares, competitors with a vasodilators market share, detailed vasodilators market segments, market trends and opportunities, and any further data you may need to thrive in the vasodilators industry. This vasodilators market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vasodilators market size has grown strongly in recent years. It will grow from $6.4 billion in 2024 to $6.83 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increased awareness and diagnosis, government initiatives and healthcare policies, rising health awareness among the people, advancements in gene therapy, and increasing adoption of artificial intelligence.

The vasodilators market size is expected to see strong growth in the next few years. It will grow to $8.75 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to the rising prevalence of hypertension and cardiovascular diseases, growing demand for advanced medical technology for cardiac diseases, the increasing geriatric population worldwide, the rising prevalence of diabetes and high blood pressure, growing importance of personalized medicine. Major trends in the forecast period include strategic mergers and acquisitions, the shift towards outpatient settings and home-based care, product innovations, technological advancements, and expansion of healthcare infrastructure.

The vasodilators market is poised for growth due to the increasing incidence of cardiovascular diseases. These diseases, which include coronary artery disease, heart failure, and stroke, are often associated with hypertension and other risk factors, fueled by sedentary lifestyles, unhealthy diets, obesity, tobacco use, and aging populations. Vasodilators play a crucial role in managing cardiovascular conditions by relaxing blood vessels, lowering blood pressure, and enhancing blood flow. For instance, in May 2024, the Centers for Disease Control and Prevention (CDC), a US government agency, reported that heart disease caused the deaths of 702,880 individuals in 2022, representing one in every five deaths. Each year in the United States, about 805,000 people suffer a heart attack. Of these, 605,000 are first-time heart attacks, while 200,000 occur in individuals who have experienced a heart attack previously. Hence, the upward trend in cardiovascular diseases is a key driver of the vasodilators market's expansion.

The increasing prevalence of sedentary lifestyles is expected to drive growth in the vasodilators market. Sedentary lifestyles, characterized by limited physical activity and prolonged periods of sitting or lying down, are becoming more common due to modern conveniences such as technology and desk-bound jobs. This trend is fueled by technological advancements and work environments that prioritize convenience over movement. Vasodilators play a crucial role in mitigating cardiovascular risks associated with sedentary lifestyles by improving blood flow and reducing hypertension. For example, data from the Centers for Disease Control and Prevention in September 2023 showed that 22 states in the US had an adult obesity rate of 35% or higher, up from 19 states in 2021, highlighting the growing impact of sedentary lifestyles. This trend is a key driver for the vasodilators market's growth.

Major players in the vasodilators market are concentrating on developing advanced products such as soluble guanylate cyclase (sGC) stimulators to gain a competitive advantage. Soluble guanylate cyclase (sGC) is an enzyme primarily found in cells, particularly in the smooth muscle cells lining blood vessels. Activation of sGC converts guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP), leading to vasodilation and increased blood flow. For instance, in September 2022, Bayer AG, a pharmaceutical and biotechnology company based in Germany, introduced Vericiguat (Verquvo), an sGC stimulator designed for adults with symptomatic chronic heart failure. This drug targets a pathway not addressed by current treatments, thus reducing the risk of cardiovascular death and hospitalization. This strategic focus on innovative products such as sGC stimulators reflects the industry's drive to offer more effective solutions for cardiovascular conditions.

Major companies operating in the vasodilators market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline Plc., Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., AstraZeneca, Mayo Foundation for Medical Education and Research (MFMER), Boehringer Ingelheim International GmbH, Bayer AG, Viatris Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen

North America was the largest region in the vasodilators market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vasodilators market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the vasodilators market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vasodilators market consists of sales of tablets, capsules, injectable solutions, transdermal patches, oral solutions, sublingual tablets, intravenous infusions, topical creams, and gels. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vasodilators Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vasodilators market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vasodilators ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vasodilators market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Arterial Dilators; Venous Dilators; Mixed Dilators
• 2) By Drugs: Nitroglycerin; Alprostadil; Minoxidil; Sorbitrate; Other Drugs
• 3) By Indication: Hypertension; Angina; Heart Failure; Other Indications
• 4) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 5) By End User: Hospitals; Homecare; Specialty Centers; Other End Users
• Subsegments:
• 1) By Arterial Dilators: Calcium Channel Blockers; Nitric Oxide Donors; Potassium Channel Activators
• 2) By Venous Dilators: Nitrates; Nitrites; Phosphodiesterase Inhibitors (PDE5 Inhibitors)
• 3) By Mixed Dilators: Alpha-Adrenergic Antagonists; Angiotensin II Receptor Blockers (ARBs); ACE Inhibitors (Angiotensin-Converting Enzyme Inhibitors)
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vasodilators Market Characteristics

3. Vasodilators Market Trends And Strategies

4. Vasodilators Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Vasodilators Growth Analysis And Strategic Analysis Framework

• 5.1. Global Vasodilators PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Vasodilators Market Growth Rate Analysis
• 5.4. Global Vasodilators Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Vasodilators Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Vasodilators Total Addressable Market (TAM)

6. Vasodilators Market Segmentation

• 6.1. Global Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Arterial Dilators
• Venous Dilators
• Mixed Dilators
• 6.2. Global Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nitroglycerin
• Alprostadil
• Minoxidil
• Sorbitrate
• Other Drugs
• 6.3. Global Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hypertension
• Angina
• Heart Failure
• Other Indications
• 6.4. Global Vasodilators Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route Of Administration
• 6.5. Global Vasodilators Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Speciality Centres
• Other End Users
• 6.6. Global Vasodilators Market, Sub-Segmentation Of Arterial Dilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Calcium Channel Blockers
• Nitric Oxide Donors
• Potassium Channel Activators
• 6.7. Global Vasodilators Market, Sub-Segmentation Of Venous Dilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nitrates
• Nitrites
• Phosphodiesterase Inhibitors (PDE5 Inhibitors)
• 6.8. Global Vasodilators Market, Sub-Segmentation Of Mixed Dilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alpha-Adrenergic Antagonists
• Angiotensin II Receptor Blockers (ARBs)
• ACE Inhibitors (Angiotensin-Converting Enzyme Inhibitors)

7. Vasodilators Market Regional And Country Analysis

• 7.1. Global Vasodilators Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Vasodilators Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vasodilators Market

• 8.1. Asia-Pacific Vasodilators Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vasodilators Market

• 9.1. China Vasodilators Market Overview
• 9.2. China Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vasodilators Market

• 10.1. India Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vasodilators Market

• 11.1. Japan Vasodilators Market Overview
• 11.2. Japan Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vasodilators Market

• 12.1. Australia Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vasodilators Market

• 13.1. Indonesia Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vasodilators Market

• 14.1. South Korea Vasodilators Market Overview
• 14.2. South Korea Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vasodilators Market

• 15.1. Western Europe Vasodilators Market Overview
• 15.2. Western Europe Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vasodilators Market

• 16.1. UK Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vasodilators Market

• 17.1. Germany Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vasodilators Market

• 18.1. France Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vasodilators Market

• 19.1. Italy Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vasodilators Market

• 20.1. Spain Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vasodilators Market

• 21.1. Eastern Europe Vasodilators Market Overview
• 21.2. Eastern Europe Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vasodilators Market

• 22.1. Russia Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vasodilators Market

• 23.1. North America Vasodilators Market Overview
• 23.2. North America Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vasodilators Market

• 24.1. USA Vasodilators Market Overview
• 24.2. USA Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vasodilators Market

• 25.1. Canada Vasodilators Market Overview
• 25.2. Canada Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vasodilators Market

• 26.1. South America Vasodilators Market Overview
• 26.2. South America Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vasodilators Market

• 27.1. Brazil Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vasodilators Market

• 28.1. Middle East Vasodilators Market Overview
• 28.2. Middle East Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vasodilators Market

• 29.1. Africa Vasodilators Market Overview
• 29.2. Africa Vasodilators Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Vasodilators Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Vasodilators Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vasodilators Market Competitive Landscape And Company Profiles

• 30.1. Vasodilators Market Competitive Landscape
• 30.2. Vasodilators Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Vasodilators Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. Abbott Laboratories
• 31.3. GlaxoSmithKline Plc.
• 31.4. Eli Lilly and Company
• 31.5. Gilead Sciences Inc.
• 31.6. Amgen Inc.
• 31.7. AstraZeneca
• 31.8. Mayo Foundation for Medical Education and Research (MFMER)
• 31.9. Boehringer Ingelheim International GmbH
• 31.10. Bayer AG
• 31.11. Viatris Inc.
• 31.12. Novo Nordisk A/S
• 31.13. Teva Pharmaceutical Industries Ltd.
• 31.14. Astellas Pharma Inc.
• 31.15. Biogen

32. Global Vasodilators Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vasodilators Market

34. Recent Developments In The Vasodilators Market

35. Vasodilators Market High Potential Countries, Segments and Strategies

• 35.1 Vasodilators Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Vasodilators Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Vasodilators Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer